Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDMTR.L Regulatory News (DMTR)

  • There is currently no data for DMTR

Technical Advisory Board Enhanced

9 Jan 2013 07:00

RNS Number : 1103V
Oxford Advanced Surfaces Group PLC
09 January 2013
 



OXFORD ADVANCED SURFACES GROUP PLC

(AIM: OXA)

 

Technical Advisory Board Enhanced

 

Oxford Advanced Surfaces Group ("OAS") the AIM listed technology developer targeting a number of global markets including consumer and industrial displays, solar panels, eyewear and the electronics and adhesion markets, has today announced a key addition to its Technical Advisory Board ("TAB").

 

From 1 January 2013, Professor Steven Abbott joined Professor Mark Moloney on the OAS TAB. Steven brings with him a wealth of industrial, scientific and commercial knowledge from both research posts and a long commercial career at ICI and MacDermid Autotype, covering all areas of the OAS target markets. He is a Fellow of the Royal Society of Chemistry and an independent consultant to global tier 1 industrial partners.

 

Adrian Meldrum, CEO said:

 

 "We are delighted to welcome Steven to the Advisory Board. He has many years of invaluable experience in the key industries and applications in which we operate and will add significant value to our technical and commercial discussions with prospective users of our technology."

 

Prof Steven Abbott commented:

 

 "I am very excited by the opportunity to work with OAS. Its technology offers a range of innovative solutions to significant problems in the world of manufacturing.."

 

 

Prof Steven Abbott received his Oxford Chemistry D Phil for work carried out at Harvard. His post-doctoral was in the Nobel Prizewinning lab of Jean-Marie Lehn at Strasbourg. He is Visiting Professor at the School of Engineering at the University of Leeds. He has worked many years in the high-tech coating industry and along the way developed a passion for computer models that could give real-world insight to complex scientific issues such as precision coating or polymer/nanoparticle solubilities. He is an independent consultant at Steven Abbott TCNF Ltd where he continues to develop software apps on solubility, surfactancy, adhesion, diffusion and advises internationally on topics as diverse as cosmetic/pharma skin delivery, organic photovoltaics, packaging films and "green" surfactant design.

 

09 January 2013

Enquiries:

 

Oxford Advances Surfaces Group Plc www.oxfordsurfaces.com

Adrian Meldrum, Chief Executive Officer

Philip Spinks, Chief Financial Officer T: 01865 854 807

 

W H Ireland Limited www.wh-ireland.co.uk

John Wakefield / Marc Davies T: 0117 945 3471

 

Lothbury FS Ltd www.lothburyfs.com

Gary Middleton / Michael Padley T: 0203 440 7620

 

 

Editors' Note

 

Oxford Advanced Surfaces Group plc (OAS) is a research-based company that develops and licenses intellectual property and products in the areas of highly reactive chemistry and anti-reflective coatings. The Company's research scientists develop innovative solutions in advanced materials and nano-technology for partners to exploit. The Company's solutions apply to real-world, practical processing and innovation challenges as novel polymer and organic materials are introduced to improve cost, weight, space and performance in new products. Initial applications include advanced adhesion, anti-reflective coatings and particle delivery in markets including conventional and plastic electronics, optics, displays, batteries and solar.

www.oxfordsurfaces.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRANKFDKOBKDDDK
Date   Source Headline
5th Jan 20237:00 amRNSCancellation - DEEPMATTER GROUP PLC
4th Jan 20238:00 amRNSHolding(s) in Company
29th Dec 20225:30 pmRNSDeepmatter Group
20th Dec 20227:00 amRNSHolding(s) in Company
19th Dec 20224:40 pmRNSSecond Price Monitoring Extn
19th Dec 20224:35 pmRNSPrice Monitoring Extension
19th Dec 20223:44 pmRNSResult of General Meeting
19th Dec 20222:05 pmRNSSecond Price Monitoring Extn
19th Dec 20222:00 pmRNSPrice Monitoring Extension
19th Dec 202211:05 amRNSSecond Price Monitoring Extn
19th Dec 202211:00 amRNSPrice Monitoring Extension
15th Dec 20224:40 pmRNSSecond Price Monitoring Extn
15th Dec 20224:35 pmRNSPrice Monitoring Extension
15th Dec 20222:05 pmRNSSecond Price Monitoring Extn
15th Dec 20222:00 pmRNSPrice Monitoring Extension
9th Dec 202211:05 amRNSSecond Price Monitoring Extn
9th Dec 202211:00 amRNSPrice Monitoring Extension
8th Dec 20228:46 amRNSHolding(s) in Company
2nd Dec 20227:00 amRNSPosting of Circular
1st Dec 20227:00 amRNSProposed Cancellation of Ordinary Shares
24th Nov 20227:00 amRNSCorporate Update
31st Oct 202212:00 pmRNSDirector/PDMR Shareholding
26th Oct 20227:00 amRNSTrading Update
26th Oct 20227:00 amRNSDeepMatter signs multi-year license agreement
26th Aug 20221:25 pmRNSHolding(s) in Company
25th Aug 20227:00 amRNSHalf Year Results
28th Jun 20227:00 amRNSDeepMatter acquires AI specialist ChemIntelligence
20th Jun 20224:41 pmRNSSecond Price Monitoring Extn
20th Jun 20224:35 pmRNSPrice Monitoring Extension
20th Jun 20222:05 pmRNSSecond Price Monitoring Extn
20th Jun 20222:00 pmRNSPrice Monitoring Extension
20th Jun 202211:05 amRNSSecond Price Monitoring Extn
20th Jun 202211:00 amRNSPrice Monitoring Extension
9th Jun 20225:26 pmRNSHolding(s) in Company
27th May 20222:30 pmRNSResult of AGM
25th May 20222:30 pmRNSIssue of Equity and TVR
23rd May 20227:00 amRNSDirectorate Change
20th May 20227:00 amRNSContract extension
11th May 20227:00 amRNSContract
27th Apr 20227:00 amRNSFinal Results
30th Mar 20224:00 pmRNSHolding(s) in Company
1st Mar 20227:00 amRNSContract
14th Feb 20227:00 amRNSDirector/PDMR Shareholding
26th Jan 20223:20 pmRNSHolding(s) in Company
26th Jan 20223:15 pmRNSHolding(s) in Company
26th Jan 20227:00 amRNSHolding(s) in Company
25th Jan 20225:45 pmRNSHolding(s) in Company
25th Jan 202212:30 pmRNSHolding(s) in Company
25th Jan 20227:00 amRNSHolding(s) in Company
25th Jan 20227:00 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.